• If you are wondering whether Danaher at around US$192.78 is priced attractively or not, the key is to look closely at what the current share price implies about the company's value.
• Over the past week the stock gained 8.2%, and it is up 5.5% over the past month, although the share price is still down 16.3% year to date and has declined 1.7% over the last year.
• These mixed returns have kept Danaher on many investors' watchlists as they reassess what a fair entry point might look like. Market attention has been influenced by ongoing sector commentary and company specific updates that continue to shape expectations about Danaher's prospects and risk profile.
• On Simply Wall St's valuation checks, Danaher scores 3 out of 6. The rest of this article will unpack how different valuation methods line up with that score, and it will conclude by outlining a more holistic way to think about value.

Approach 1: Danaher Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Danaher might be worth today by projecting future cash flows and discounting them back to a single present value. It is essentially asking what those future dollars are worth right now.

For Danaher, the latest twelve month Free Cash Flow is about $5.10b. Using a 2 Stage Free Cash Flow to Equity model, Simply Wall St combines analyst estimates for the next few years with longer term extrapolations, including a projected Free Cash Flow of $11.13b in 2035, all expressed in $. Each of those future cash flow figures is discounted back to today and summed.

On this basis, the DCF model suggests an estimated intrinsic value of about $237.49 per share. Compared to the current share price of around $192.78, that implies an intrinsic discount of 18.8%, indicating that Danaher stock is trading below this particular estimate of fair value.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 18.8%. Track this in your watchlist or portfolio, or discover 42 more high quality undervalued stocks.

Approach 2: Danaher Price vs Earnings

For profitable companies like Danaher, the P/E ratio is a useful way to gauge how much you are paying for each dollar of earnings. It links the share price directly to earnings and helps you compare what the market is willing to pay for different stocks in similar sectors.

What counts as a normal or fair P/E depends in part on how fast earnings are expected to grow and how risky those earnings are. Higher growth or lower perceived risk can justify a higher P/E, while slower growth or higher risk typically lines up with a lower multiple.

Danaher currently trades on a P/E of 37.13x. That is close to the Life Sciences industry average of 36.71x and below the peer group average of 39.46x. Simply Wall St also calculates a Fair Ratio of 28.40x for Danaher, a proprietary estimate of what the P/E might be based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it is tailored to Danaher rather than broad peer groups, this Fair Ratio can provide a more customised benchmark. Comparing 37.13x to the Fair Ratio of 28.40x suggests the stock screens as overvalued on this measure.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Danaher Narrative

Earlier we mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Danaher to the numbers by linking your view of its business, forecasts for revenue, earnings and margins, and your own fair value estimate. You can then compare that fair value to the current price to help you decide what action, if any, makes sense.

A Narrative is created and shared within the Simply Wall St Community page, and it is updated automatically when new information like Danaher news, earnings or guidance is added. This helps your story and valuation stay aligned with the latest data without you needing to rebuild a model from scratch.

For Danaher, one investor might lean on the higher fair value of about US$310 and build a story that emphasizes recurring revenue, precision medicine exposure and opportunities from Masimo. Another investor might anchor closer to US$200 and focus more on risks around China policy, funding cycles in life science tools and bioprocessing concentration. Both views are visible as distinct Narratives that you can compare against the current share price.

Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.